相似文献
1
The Past, Present, and Future in Management of Small Renal Masses.
J Oncol. 2015;2015:364807. doi: 10.1155/2015/364807. Epub 2015 Sep 30.
2
Management of Small Renal Masses.
Cancer Treat Res. 2018;175:105-126. doi: 10.1007/978-3-319-93339-9_5.
3
Contemporary Issues Surrounding Small Renal Masses: Evaluation, Diagnostic Biopsy, Nephron Sparing, and Novel Treatment Modalities.
Oncology (Williston Park). 2016 Jun;30(6):507-14.
4
Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation.
J Clin Oncol. 2018 Dec 20;36(36):3591-3600. doi: 10.1200/JCO.2018.79.2341. Epub 2018 Oct 29.
5
Should Small Renal Masses Be Biopsied?
Curr Urol Rep. 2017 Jan;18(1):7. doi: 10.1007/s11934-017-0653-3.
6
Risk prediction in the management of small renal masses.
Curr Opin Urol. 2012 Sep;22(5):347-52. doi: 10.1097/MOU.0b013e328355ede9.
7
The role of surveillance in the management of small renal masses.
ScientificWorldJournal. 2007 Apr 30;7:860-8. doi: 10.1100/tsw.2007.157.
8
Active surveillance of small renal masses: progression patterns of early stage kidney cancer.
Eur Urol. 2011 Jul;60(1):39-44. doi: 10.1016/j.eururo.2011.03.030. Epub 2011 Apr 1.
9
The current management of small renal masses.
Curr Opin Support Palliat Care. 2009 Sep;3(3):180-5. doi: 10.1097/SPC.0b013e32832e9c6d.
10
A Review on the Management of Small Renal Masses: Active Surveillance Versus Surgery.
Anticancer Agents Med Chem. 2018;18(7):940-950. doi: 10.2174/1871520617666171113123443.
引用本文的文献
1
Histopathologic features and parameters predicting recurrence potential of small renal masses.
Curr Urol. 2025 May;19(3):192-197. doi: 10.1097/CU9.0000000000000175. Epub 2023 Jan 17.
2
Diagnostic Value of Contrast-Enhanced Ultrasound in Differentiating Malignant from Benign Small Renal Masses After CT/MRI.
J Clin Med. 2024 Oct 29;13(21):6478. doi: 10.3390/jcm13216478.
3
The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms.
J Cancer Res Clin Oncol. 2024 Mar 12;150(3):122. doi: 10.1007/s00432-023-05571-8.
4
Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study.
Sci Rep. 2024 Feb 27;14(1):4740. doi: 10.1038/s41598-024-54052-6.
5
Scientific Status Quo of Small Renal Lesions: Diagnostic Assessment and Radiomics.
J Clin Med. 2024 Jan 18;13(2):547. doi: 10.3390/jcm13020547.
6
Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance.
BJUI Compass. 2022 Mar 3;3(4):291-297. doi: 10.1002/bco2.141. eCollection 2022 Jul.
7
The value of surveying the kidneys during pelvic ultrasound examinations.
Australas J Ultrasound Med. 2019 Jan 23;22(2):118-128. doi: 10.1002/ajum.12122. eCollection 2019 May.
8
The impact of a multidisciplinary small renal mass clinic on patient treatment decisions.
Can Urol Assoc J. 2022 Feb;16(2):35-40. doi: 10.5489/cuaj.7307.
9
Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database.
Investig Clin Urol. 2020 May;61(3):260-268. doi: 10.4111/icu.2020.61.3.260. Epub 2020 Mar 10.
10
Percutaneous irreversible electroporation for the treatment of small renal masses: The first Canadian case series.
Can Urol Assoc J. 2019 Sep;13(9):E263-E267. doi: 10.5489/cuaj.5728.
本文引用的文献
1
Comparison of renal function detriments after local tumor ablation or partial nephrectomy for renal cell carcinoma.
World J Urol. 2016 Mar;34(3):383-9. doi: 10.1007/s00345-015-1606-4. Epub 2015 Jun 6.
2
Management of Small Kidney Cancers in the New Millennium: Contemporary Trends and Outcomes in a Population-Based Cohort.
JAMA Surg. 2015 Jul;150(7):664-72. doi: 10.1001/jamasurg.2015.0294.
3
Standard of Care for Small Renal Masses in the 21st Century.
JAMA Surg. 2015 Jul;150(7):672-3. doi: 10.1001/jamasurg.2015.0440.
4
Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis.
Urol Oncol. 2015 Jul;33(7):303-9. doi: 10.1016/j.urolonc.2015.04.001. Epub 2015 May 13.
5
A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
Contemp Clin Trials. 2015 Jul;43:10-9. doi: 10.1016/j.cct.2015.05.002. Epub 2015 May 9.
6
Percutaneous CT-Guided Radiofrequency Ablation of Solitary Small Renal Masses: A Single Center Experience.
Rofo. 2015 Jul;187(7):577-83. doi: 10.1055/s-0034-1399340. Epub 2015 Apr 21.
7
The natural history and predictors for intervention in patients with small renal mass undergoing active surveillance.
Adv Urol. 2015;2015:692014. doi: 10.1155/2015/692014. Epub 2015 Apr 15.
8
Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience.
Eur Urol. 2015 Dec;68(6):1007-13. doi: 10.1016/j.eururo.2015.04.004. Epub 2015 Apr 18.
9
The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol.
BMC Cancer. 2015 Mar 22;15:165. doi: 10.1186/s12885-015-1189-x.
10
Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.
Eur Urol. 2015 Sep;68(3):408-15. doi: 10.1016/j.eururo.2015.02.001. Epub 2015 Feb 16.
Zotero 插件